EcoDrugPlus

Tyrosinase

Ensembl ID : ENSLBEG00000013616
Gene Symbol: TYR
2 Cross references
198 Possible Orthologues:

Tyrosine Hydroxylase

Ensembl ID : ENSLBEG00000002647
Gene Symbol: TH
3 Cross references
187 Possible Orthologues:

Tyrosine Kinase With Immunoglobulin Like And Egf Like Domains 1

Ensembl ID : ENSLBEG00000014097
Gene Symbol: TIE1
3 Cross references
205 Possible Orthologues:

Tyrosine-Protein Kinase Jak2-Like

Ensembl ID : ENSLBEG00000024071
Gene Symbol: LOC109981196
3 Cross references
199 Possible Orthologues:

Tyrosine-Protein Kinase Lyn-Like

Ensembl ID : ENSLBEG00000010764
Gene Symbol: LOC109997596
3 Cross references
195 Possible Orthologues:

Tyrosine-Protein Kinase Fyna

Ensembl ID : ENSLBEG00000028601
Gene Symbol: LOC109987579
3 Cross references
191 Possible Orthologues:

Tyrosine-Protein Kinase Yes-Like

Ensembl ID : ENSLBEG00000015357
Gene Symbol: LOC109985019
3 Cross references
206 Possible Orthologues:

Ubiquitin-Like Protein Fubi

Ensembl ID : ENSLBEG00000024699
Gene Symbol: LOC109982950
3 Cross references
300 Possible Orthologues:

Uncharacterized Loc109992014

Ensembl ID : ENSLBEG00000011393
Gene Symbol: LOC109992014
2 Cross references
190 Possible Orthologues:

Uncharacterized Loc109996964

Ensembl ID : ENSLBEG00000011001
Gene Symbol: LOC109996964
2 Cross references
196 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 3a

Ensembl ID : ENSLBEG00000022540
Gene Symbol: AKT3A
1 Cross references
203 Possible Orthologues:

Vascular Endothelial Growth Factor A

Ensembl ID : ENSLBEG00000003354
Gene Symbol: VEGFA
3 Cross references
201 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).